In a landmark move that marks the largest acquisition in its 90-year history, Italian pharmaceutical giant Chiesi has agreed to…
Read More
Johns Hopkins Researchers Uncover How Fusion Gene Condensates Drive Rare Kidney Cancer Progression and Propose New Therapeutic Pathways
In a significant advancement for oncology and molecular biology, a multidisciplinary team of investigators at the Johns Hopkins Kimmel Cancer…
Read More
LEO Pharma Acquires Gene Therapy Pioneer Replay to Revolutionize Treatment for Rare Genetic Dermatological Diseases
In a landmark move poised to redefine the landscape of dermatological therapeutics, LEO Pharma, a global leader in medical dermatology,…
Read More
Rethinking Evidence Generation for Ultra-Rare Diseases
The landscape of drug development for ultra-rare diseases is undergoing a significant transformation, driven by the U.S. Food and Drug…
Read More
King’s College London Researchers Identify a New Form of Aluminum as a Sustainable and Cost-Effective Alternative to Rare Earth Metals
In a landmark development for the field of inorganic chemistry, a team of scientists at King’s College London has announced…
Read More
BioMarin Pharmaceutical Finalizes $4.8 Billion Acquisition of Amicus Therapeutics, Bolstering Rare Disease Portfolio
BioMarin Pharmaceutical has officially concluded its substantial acquisition of Amicus Therapeutics, a move that promises to significantly expand BioMarin’s footprint…
Read More
Merck KGaA and Remepy Forge Groundbreaking Partnership to Pioneer "Hybrid Drugs" for Rare Cancers
In a move that signals a significant shift in pharmaceutical innovation, Merck KGaA has announced a strategic collaboration with Remepy,…
Read More
Johns Hopkins Study Reveals How Liquid Droplets Formed by Fusion Genes Drive Rare Kidney Cancer Progression
In a significant advancement for molecular oncology, investigators at the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins Bloomberg…
Read More
Rethinking Evidence Generation for Ultra-Rare Diseases
Developing effective treatments for ultra-rare diseases has long presented a profound paradox for the biopharmaceutical industry and regulatory bodies. While…
Read More
Terremoto Biosciences Secures $108 Million Series C to Advance Next-Generation AKT1 Inhibitors for Oncology and Rare Diseases
Terremoto Biosciences, a pioneering biotechnology company at the forefront of developing novel therapeutics targeting the PI3K/AKT pathway, announced today the…
Read MoreYOU MAY HAVE MISSED
